Evidence map›Paper›PMID 32941052›Full record

ReviewAnnals of internal medicine2021

Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors.

Eric A Meyerowitz, Aaron Richterman, Rajesh T Gandhi, Paul E Sax

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06597370 (Immunogenicity Induced by COVID-19 Vaccines in Mexican Population), which is not on this map. Cited by 393 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
393citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06597370 completednot on this map

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population: mRNA Expression for IgG Anti-spike

Typeobservational_patient_registrySponsorNational Polytechnic Institute, MexicoRan2021 to 2021Enrolled80ConditionsCOVID-19 VaccineArmsGene expression mRNA of IgG anti-spike
3 · Its place in the literature

Who cites it

393 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article

333 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Eric A MeyerowitzMontefiore Medical Center, Bronx, New York (E.A.M.).ORCID 0000-0001-7954-6548
Aaron RichtermanHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (A.R.).ORCID 0000-0001-7920-7191
Rajesh T GandhiMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (R.T.G.).
Paul E SaxHarvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts (P.E.S.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), has spread globally in a few short months. Substantial evidence now supports preliminary conclusions about transmission that can inform rational, evidence-based policies and reduce misinformation on this critical topic. This article presents a comprehensive review of the evidence on transmission of this virus. Although several experimental studies have cultured live virus from aerosols and surfaces hours after inoculation, the real-world studies that detect viral RNA in the environment report very low levels, and few have isolated viable virus. Strong evidence from case and cluster reports indicates that respiratory transmission is dominant, with proximity and ventilation being key determinants of transmission risk. In the few cases where direct contact or fomite transmission is presumed, respiratory transmission has not been completely excluded. Infectiousness peaks around a day before symptom onset and declines within a week of symptom onset, and no late linked transmissions (after a patient has had symptoms for about a week) have been documented. The virus has heterogeneous transmission dynamics: Most persons do not transmit virus, whereas some cause many secondary cases in transmission clusters called "superspreading events." Evidence-based policies and practices should incorporate the accumulating knowledge about transmission of SARS-CoV-2 to help educate the public and slow the spread of this virus.

Indexed as

AerosolsCOVID-19Equipment ContaminationFomitesHumansRisk FactorsRNA, ViralSARS-CoV-2AerosolsRNA, Viral

Identifiers

PMID32941052
PMCPMC7505025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.